At a glance
- Originator Amgen
- Class Antipsychotics; Small molecules
- Mechanism of Action Phosphodiesterase 10A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Schizoaffective disorder; Schizophrenia
Most Recent Events
- 14 Oct 2015 No recent reports on development identified - Phase-I for Schizoaffective disorder in USA (PO)
- 14 Oct 2015 No recent reports on development identified - Phase-I for Schizophrenia in USA (PO)
- 30 Jun 2012 Amgen terminates a phase I trial in Schizophrenia and Schizoaffective disorder in USA (NCT01568203)